Clover and Ascentage Pharma Announce Clinical Collaboration to Evaluate Recombinant Human TRAIL-Trimer Fusion Protein, SCB-313, in Combination with IAP Antagonist, APG-1387 for the Treatment of Peritoneal Carcinomatosis

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability